Ratings HAEMATO AG Xetra

Equities

End-of-day quote Xetra Other stock markets 06:00:00 2024-02-04 pm EST			5-day change	1st Jan Change
26.2 ^EUR	-0.76%		-1.50%	-5.76%

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.25 for the 2023 fiscal year.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company does not generate enough profits, which is an alarming weak point.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HAEMATO AG	-5.76%	95.79M		-
MERCK KGAA	+6.97%	71.94B		A
SK BIOPHARMACEUTICALS CO., LTD.	-10.86%	5.13B		A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+46.43%	4.66B		-
YUHAN CORPORATION	+5.38%	3.97B		B-
BETTA PHARMACEUTICALS CO., LTD.	-16.20%	2.55B		C-
INDIVIOR PLC	+21.10%	2.41B		B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.20%	2.36B		-
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.92%	2.21B	-	-
SUPERNUS PHARMACEUTICALS, INC.	+8.47%	1.71B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality